Industries We Serve

Microbial Systems. Immune Innovation. Beyond the Cell.

At Mika Biologics, we believe the microbial cell factory is not just a tool — it is the engine of the future bioeconomy. From rare disease therapies to global vaccines, from CRISPR tools to alternative proteins, microbes power the breakthroughs that matter most.

While many CDMOs dilute their focus across mammalian, microbial, and small molecule platforms, Mika is different. We are a specialist microbial-first CDMO, the best in the U.S., the world, and the galaxy (we can’t yet make claims in other universes). Our expertise in E. coli, yeast, fungi, phages, and cell-free systems makes us the partner of choice for innovators tackling the hardest problems in biotech and beyond.

We don’t try to be everything to everyone. We focus on nine core verticals, each deeply tied to our microbial-first identity. This focus allows us to combine scientific depth, technical mastery, and regulatory fluency with the agility that innovators demand.

Our Industry Verticals

Below you’ll find the major industries Mika serves, each with its own dedicated page. This overview introduces our value in each sector and how our microbial-first approach makes us indispensable.

Biopharma & Biotech

Immunotherapy. Oncology. Cell & Gene Therapy Enablers.

Biopharma companies need speed to clinic, technical mastery of difficult proteins, and scalable GMP production. Cytokines, VLP vaccines, CRISPR proteins, and nanoparticles are central to today’s immunotherapy and oncology pipelines — but most CDMOs shy away from them.

Mika thrives here. We specialize in the “hard proteins” that others avoid: cytokines that misfold, checkpoint ligands that need glycoengineering, nanoparticle scaffolds that demand rigorous analytics. With microbial-first systems, we deliver faster INDs, lower COGs, and orphan-scale GMP runs tailored to the biotech lifecycle.

Rare Disease & Orphan Drugs

Orphan-Scale. Patient-Centered. Rare Is Normal.

For rare disease innovators, every gram of protein matters. Lysosomal enzymes, orphan cytokines, and small-batch plasmids often fall through the cracks at large CDMOs. Mika makes them our core mission.

We provide 1–2000 L orphan-scale GMP runs, proprietary folding workflows for rare enzymes, endotoxin-free plasmids, and regulatory support for orphan drug designation. We thrive on programs others decline, ensuring patients with rare conditions are never overlooked.

Synthetic Biology & Tools

CRISPR. Polymerases. Ligases. Engineered Enzymes.

The synbio revolution runs on tools: nucleases, polymerases, ligases, and engineered enzymes. Off-the-shelf is not enough — companies need custom, validated, GMP-ready proteins.

Mika is the only CDMO to treat synbio tools as a flagship service line. We manufacture CRISPR nucleases, high-fidelity polymerases, thermostable ligases, and novel enzymes at discovery through GMP scale. Our microbial-first and cell-free platforms enable rapid prototyping while our GMP systems bridge tools from the lab into diagnostics and therapeutics.

Vaccines & Global Health

VLPs. Nanoparticles. Pandemic Readiness.

Global health requires vaccines that are fast, scalable, affordable, and stable. Microbial platforms are uniquely suited to meet these needs.

At Mika, we produce VLPs, microbial scaffolds, nanoparticles, and engineered probiotics that serve oncology vaccines, pandemic response, and neglected diseases. We provide lyophilized formulations for global distribution, WHO PQ support, and partner capacity up to 20,000 L for outbreak readiness.

Alternative Proteins & Enzyme Applications

Precision Fermentation. Food Tech. Industrial Biocatalysts.

Biology isn’t just medicine — it’s infrastructure. Mika supports food-tech, alternative protein, and industrial enzyme innovators with the same microbial-first rigor we bring to biopharma.

We manufacture casein, whey proteins, mycoproteins, and nutraceutical proteins via precision fermentation, as well as industrial enzymes (carbohydrases, proteases, lipases) for sustainable chemistry. Our dual focus on COGs optimization and regulatory support (GRAS, EFSA, FDA) makes us a unique partner bridging pharma-level rigor with food-scale sustainability.

Engineered Probiotics (LBPs)

Living Medicines. Microbiome Therapeutics.

The microbiome is the next frontier of medicine. Engineered probiotics (live biotherapeutic products, LBPs) are designed to modulate immunity, deliver payloads, and restore balance from within.

Mika is one of the few CDMOs with anaerobic fermentation, GMP containment, and formulation expertise for LBPs. We engineer E. coli Nissle, Lactobacillus, Bifidobacterium, and next-gen anaerobes with CRISPR tools, kill-switches, and metabolic rewiring. We provide banking, stability, capsule/lyophilized formats, and regulatory support for FDA/EMA LBP pathways.

Immune Biologics

Cytokines. Checkpoints. Immunomodulators.

Immunotherapies are built on cytokines, checkpoint proteins, and modulators. These proteins are fragile, prone to misfolding, and often avoided by other CDMOs. At Mika, they are our specialty.

We manufacture IL-2, IL-7, GM-CSF, interferons, and checkpoint ligands with refolding workflows, chaperone co-expression, and bioactivity validation assays. We don’t just produce protein — we prove function, helping biopharma innovators accelerate clinical programs.

Fungal & Yeast Expression Systems

Pichia. Saccharomyces. Aspergillus. Trichoderma.

Yeast and fungi are powerhouses of secretion and glycosylation. Yet most CDMOs underutilize them. At Mika, they are core platforms.

We harness Pichia pastoris for glycoengineered proteins, Saccharomyces for VLPs and GRAS applications, and Aspergillus/Trichoderma for carbohydrases and specialty metabolites. These systems bridge therapeutics, industrial enzymes, and alternative proteins.

Endotoxin-Free Biologics

Cleaner. Safer. Ready from the Start.

Endotoxins are the hidden tax of microbial biologics. Most CDMOs address them late, with costly purification. At Mika, we start endotoxin-free from the source.

Using ClearColi® strains, engineered hosts, and endotoxin-reduced workflows, we deliver plasmids, cytokines, and proteins that pass QC the first time. This reduces regulatory risk, lowers cost, and accelerates IND submissions. We are the first CDMO to make endotoxin-free a dedicated service line.

Biologic Nanoparticles

Self-Assembly. Precision Delivery. Nanomedicine.

The future of biologics won’t always be antibodies or enzymes — it will be nanoparticles. Protein-based, self-assembling biologic nanoparticles serve as vaccine scaffolds, drug carriers, and biomaterials.

Mika manufactures VLPs, protein cages, enzyme nanoreactors, and engineered scaffolds, validated with EM, DLS, and functional assays. We integrate synthetic biology, immunology, and nanotech to make biologic nanoparticles not just experimental curiosities, but clinical-grade platforms.

Why Choose Mika Across Industries?

While our industries are diverse, our value pillars are the same:

1. Microbial-First Focus – not a side offering, but our identity.
2. Technical Elegance – solving folding, solubility, and activity challenges others avoid.
3. Orphan-Scale Agility – 10–200 L runs embraced, not ignored.
4. GMP Rigor – FDA/EMA compliance, global regulatory alignment.
5. Galaxy-Class Thought Leadership – we don’t just manufacture; we define the future of microbial biologics.

Closing Statement

From oncology vaccines to precision fermentation dairy, from CRISPR enzymes to orphan cytokines, Mika Biologics exists to empower innovators. We thrive in niches, master microbial systems, and deliver where others refuse.

We don’t just serve industries. We shape them.